Skip to content

Open calls · Co-funding for institutions · Medicine

European Partnership for Pandemic Preparedness (Phase 2)

European Commission · Horizon Europe · HORIZON-HLTH-2026-03-DISEASE-13

Go to the funder’s page
Opens10 Feb 2027

Deadlines

  • 13 Apr 2027 Deadline in 152 days

Time of day: 17:00 Brussels time.

Who can apply

Countries
Applicants from any country can take part. Funding is usually limited to the EU, associated countries and listed low- and middle-income countries; sanctions apply to some.
Who applies
An organisation

Money

Per project
up to €63M per project
Total budget
€63M
Expected awards
1

About the call

Expected Outcome:
This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Tackling diseases and reducing disease burden”. Proposals under this topic should aim to deliver results that are directed at, tailored towards and contributing to all the following expected outcomes:

• The EU offers a valued operational network of clinical research sites (both interventional and observational) that have the capacity to implement well-coordinated large-scale multi-country quality clinical studies in different target populations, which are able to smoothly transition to interventions relevant for cross-border health threats in readiness for or response to a public health emergency.

• Key stakeholders, including relevant EU and national entities, the scientific communities, policymakers and funders enhance their collaboration and coordination to strengthen research on pandemic preparedness and response, forming a strong, structured and comprehensive ecosystem with shared evidence, tools and methodologies cutting across sectors.

• Research funders, policymakers, relevant EU and national entities, and the research community recognise and rapidly close relevant research and related infrastructure gaps and break existing silos on pandemic preparedness research and response, adopting a One Health approach.

• Healthcare authorities, regulatory authorities, policymakers and other stakeholders utilise research results to develop evidence-based strategies and policies for pandemic preparedness and response, and deploy good practices to European countries and regions, and beyond whenever relevant.

• The research community benefits from and uses an improved comprehensive knowledge framework integrating the EU, national/regional data and information infrastructures to improve transnational research in the area of pandemic preparedness and response.

• The EU is strengthened as an internationally recognised actor for pandemic preparedness research and response, as such substantially contributing to global cooperation and coordination.
Scope:
This topic targets an action under Article 24(2) HE Regulation aiming to add additional activities to existing grant agreements, together with additional partners (if relevant) that would deliver on those activities. The award of a grant to continue the partnership in accordance with this call should be based on a proposal submitted by the coordinator of the consortium funded under topic HORIZON-HLTH-2024-DISEASE-12-01: “European Partnership for Pandemic Preparedness” and the additional activities (which may include additional partners) to be funded by the grant, such as the close coordination with the Clinical Trial Coordination Mechanism (CT-CM) [1] , should be subject to an evaluation. The partnership should be firmly anchored within the framework of the European Health Union package [2] and ensure synergies with the European Health Emergency Preparedness and Response Authority (HERA) and other relevant Commission services. The partnership’s activities are expected to be key enablers of the EU Global Health Strategy [3] . Taking into account that the present action is a continuation of the topic HORIZON-HLTH-2024-DISEASE-12-01: “European Partnership for Pandemic Preparedness” and foresees an amendment to an existing grant agreement, the proposal should present the additional activities (including additional partners) to be covered by the award primarily in terms of grant agreement revisions. The existing action, the “Be Ready Now - European Partnership for Pandemic Preparedness” (BE READY NOW) can only reasonably be enhanced and enlarged on the basis of the existing consortium [4] , as the co-funded framework established cannot simply be replaced without significant disruption, given the top-quality, long-term expertise and wide coverage of the beneficiaries comprising this consortium.
The partnership should contribute to the actions proposed in the Joint Communication on the European Preparedness Union Strategy (JOIN(2025) 130 final [5] ) which recognises the essential contribution of research and innovation to allow “continuously adapted, optimised and state-of-the-art responses to crisis”. It should also contribute to the “Strategy for European Life Sciences” [6] . Synergies with EU programmes such as EU4Health Programme (2021-2027) [7] or the Digital Europe Programme [8] are encouraged.
The co-funded Partnership for Pandemic Preparedness should enable improved coordination and cooperation on national and European levels (and contributing globally), building on the Strategic Research and Innovation Agenda (SRIA) [9] established in the first phase of the partnership. The partnership’s implementation is grounded in coordinating and jointly funding transnational research, combined with a strong focus on integrative ‘in-house’ activities, ultimately reinforcing the readiness of Europe’s research ecosystem. As a continuation of an existing action, the proposal should present the additional activities (including additional partners) to be covered by the award primarily in terms of grant agreement revisions.
The partnership should cover the full scope of preparedness research, ranging from basic and pre-clinical research, to clinical, public health, social sciences and implementation research. The partnership will consider the interplay between environmental, ecological and climatic factors and the emergence and spread of health threats and will adopt a One Health approach to better understand and mitigate the risks of emerging infectious diseases.
Of particular interest is the consolidation and further development of the ever-warm clinical research network, comprising both observational and interventional studies, ensuring continuous clinical research activity across diverse sites, and with the in-built capacity to rapidly respond to public health emergencies. In this regard, the partnership should…

Text from the funder (European Commission, CC BY 4.0).

Conditions in full

"> General conditions
1. Admissibility Conditions, proposal page limit and layout
Admissibility conditions are  described in Annex A and Annex E of the Horizon Europe Work Programme General Annexes.
Proposal page limits and layout are described in Part B of the Application Form available in the Submission System.

2. Eligible Countries
Eligible countries are described in Annex B of the Work Programme General Annexes.
A number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making funding available for their participants in Horizon Europe projects. See the information in the Horizon Europe Programme Guide .

3. Other Eligibility Conditions
The proposal must be submitted by the coordinator of the consortium funded under topic HORIZON-HLTH-2024-DISEASE-12-01: “European Partnership for Pandemic Preparedness”. This eligibility condition is without prejudice to the possibility to include additional partners.

In recognition of the opening of the US National Institutes of Health’s programmes to European researchers, any legal entity established in the United States of America is eligible to receive Union funding. Because the US contribution will be considered for the calculation of the EU contribution to the partnership, the concerned consortium of research funders from eligible EU Members States and Associated Countries must expressly agree to this participation.

Subject to restrictions for the protection of European communication networks.

Other eligibility conditions are described in Annex B of the Work Programme General Annexes.

4. Financial and operational capacity and exclusion
Financial and operational capacity and exclusion are described in Annex C of the Work Programme General Annexes.

5a. Evaluation and award: Award criteria, scoring and thresholds
The evaluation will take into account the existing context and the scope of the initial evaluation as relevant, and related obligations enshrined in the grant agreement.
If the proposal is successful, the next stage of the procedure will be grant agreement amendment preparations.
If the outcome of amendment preparations is an award decision, the coordinator of the consortium funded under topic HORIZON-HLTH-2024-DISEASE-12-01: “European Partnership for Pandemic Preparedness” will be invited to submit an amendment to the grant agreement, on behalf of the beneficiaries.

Award criteria, scoring and thresholds are described in Annex D of the Work Programme General Annexes.

5b. Evaluation and award: Submission and evaluation processes
The thresholds for each criterion will be 4 (Excellence), 4 (Impact) and 4 (Implementation). The cumulative threshold will be 12.

Submission and evaluation processes are described in Annex F of the Work Programme General Annexes and the Online Manual .

5c. Evaluation and award: Indicative timeline for evaluation and grant agreement
Indicative timeline for evaluation and grant agreement are described in Annex F of the Work Programme General Annexes.

6. Legal and financial set-up of the grants
This action is intended to be implemented in the form of an amendment of the grant agreement concluded pursuant to Article 24(2) of the Horizon Europe Regulation.
For the additional activities covered by this action:

• The funding rate is 50% of the eligible costs. This is justified by the pooling of proposers' in-kind contributions and in-house activities and by the nature of activities to be performed: in addition of joint calls, sustain and further develop the EU-wide networks and infrastructures for clinical research, and in particular a network of ever-warm clinical trial sites.

• Beneficiaries may provide financial support to third parties (FSTP). The support to third parties can only be provided in the form of grants. As a co-funded European Partnership, providing financial support to third parties is a core activity of this action in order to achieve its objectives. Consequently,…

We sort calls into fields, career stages and countries automatically. Always check the conditions on the funder’s page before you apply.

Discussion

Applying too? Looking for partners? Ask here.